Last $142.42 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US
As of 4:30 PM 08/11/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Key Developments

ALK Submits Registration Application for House Dust Mite SLIT-Tablet in Europe

ALK announced that a registration application for the house dust mite sublingual allergy immunotherapy tablet has been submitted in Europe. House dust mites are the most common cause of respiratory allergic disease, affecting an estimated 35 million adult Europeans of whom more than 3 million are poorly controlled with current standard pharmacotherapy. ALK's regulatory filing for the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the European health authorities via the Decentralised Procedure with Germany as the Reference Member State. The regulatory review process is expected to take around 12 months, which means that, subject to approval, the first launches could possibly take place in 2016.

ALK-Abelló A/S Reports Unaudited Group Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance For the Full Year of 2014

ALK-Abelló A/S reported unaudited group earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of DKK 522 million against DKK 509 million for the same period a year ago. Operating profit (EBIT) before special items was DKK 22 million against DKK 22 million a year ago. Operating profit (EBIT) was DKK 18 million against DKK 17 million for the same period a year ago. Profit before tax (EBT) was DKK 43 million against DKK 16 million a year ago. Net profit was DKK 26 million against DKK 9 million a year ago. Earnings per share (DEPS), diluted was DKK 2.63 against DKK 0.92 a year ago. Operating profit before depreciation and amortisation (EBITDA) before special items was DKK 57 million against DKK 54 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was DKK 53 million against DKK 49 million a year ago. For the nine months, the company reported revenue of DKK 1,821 million against DKK 1,651 million for the same period a year ago. Operating profit before depreciation and amortisation (EBITDA) before special items was DKK 377 million against DKK 148 million a year ago. Operating profit before depreciation and amortisation (EBITDA) was DKK 347 million against DKK 141 million a year ago. Operating profit (EBIT) before special items was DKK 275 million against DKK 54 million a year ago. Operating profit (EBIT) was DKK 245 million against DKK 47 million for the same period a year ago. Profit before tax (EBT) was DKK 279 million against DKK 37 million a year ago. Net profit was DKK 165 million against DKK 21 million a year ago. Earnings per share – diluted were DKK 16.7 against DKK 2.2 a year ago. Cash flow from operating activities was DKK 163 million against DKK 2 million a year ago. Cash flow per share (CFPS) was DKK 16.9 against DKK 0.2 a year ago. Free cash flow was DKK 26 million against an outflow of DKK 154 million a year ago. The increase in cash flow from operating activities was primarily driven by the growth in net profit. The cash flow was negatively impacted by changes in working capital, largely due to build-up of HDM SLIT-tablet inventories. Additions, intangible assets were DKK 44 million against DKK 46 million a year ago. Additions, tangible assets were DKK 75 million against DKK 118 million a year ago. For the year 2014, the company’s revenue is still expected at approximately DKK 2,400 million. EBITDA before special items is still expected at approximately DKK 450 million. CAPEX is still expected to total approximately DKK 200 million. Free cash flow is expected to be positive.

ALK-Abelló A/S, Q3 2014 Earnings Call, Nov 14, 2014

ALK-Abelló A/S, Q3 2014 Earnings Call, Nov 14, 2014

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014

ALK-Abelló A/S Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-05-2014 . Venue: London, United Kingdom. Speakers: Per Plotnikof, Director of IR & Strategic Planning.

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014

ALK-Abelló A/S Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 through Sep-11-2014. Venue: The Grand Hyatt Hotel, New York, New York, United States. Presentation Date & Speakers: Sep-09-2014, Jens Bager, Chief Executive Officer, President and Member of the Board of Management.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $142.42 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 22.50 GBp 0.00
DBV Technologies SA €40.14 EUR +0.03
Merck & Co Inc $59.75 USD +0.41
Sanofi €77.18 EUR -0.05
Stallergenes SA €49.14 EUR -0.31
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 33.3x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 31.1x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.